TRAIL Agonist Depot Formulation for Resistant Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current TRAIL-based therapies for cancer are limited by TRAIL resistance in cancer cells, which is due to reduced cell surface DR expression, inhibited caspase-8 activation, upregulated anti-apoptotic molecules, and reduced pro-apoptotic markers, leading to inadequate clinical efficacy despite promising preclinical results.
Innovation Solution
Development of compositions comprising a TRAIL receptor agonist combined with sensitizing agents such as pharmacological inhibitors of XIAP, BCL-XL, and CDK4/6, and the use of thermally responsive polypeptides to form sustained release depots, enhancing the sensitivity of cancer cells to TRAIL-resistant cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TRAIL receptor agonists are used to treat cancer, then cancer cell killing activity is improved, but TRAIL resistance in cancer cells limits clinical efficacy
Solution Approach 1:
The patent combines TRAIL receptor agonists with sensitizing agents (inhibitors of XIAP, BCL-XL, and CDK4/6) to overcome TRAIL resistance. This combination therapy merges two therapeutic approaches: TRAIL-induced apoptosis and pharmacological inhibition of resistance mechanisms, thereby restoring sensitivity and improving cancer cell killing activity in resistant cell lines.
Solution Approach 2:
Sensitizing agents act as intermediaries between TRAIL receptor agonists and TRAIL-resistant cancer cells. These agents modulate the cellular environment by inhibiting anti-apoptotic pathways (XIAP, BCL-XL) and cell cycle progression (CDK4/6), thereby mediating the effect of TRAIL and enabling it to overcome resistance mechanisms.
2Ease of operation
If TRAIL monotherapy is used, then treatment simplicity is maintained, but synergistic cytotoxicity and apoptosis are not achieved in TRAIL-resistant cancers
Solution Approach 1:
The patent merges TRAIL receptor agonist therapy with sensitizing agent therapy to achieve synergistic cytotoxicity. This combination targets multiple resistance mechanisms simultaneously (apoptotic pathway inhibition via XIAP/BCL-XL and cell cycle progression via CDK4/6), producing a therapeutic effect greater than the sum of individual agents in TRAIL-resistant cancer cell lines.
3Duration of action of moving object
If short-acting TRAIL formulations are used, then administration frequency is reduced, but prolonged therapeutic effects and improved tumor regression are not achieved
Solution Approach 1:
The patent uses thermally responsive polypeptides to create sustained-release depots that pre-release TRAIL receptor agonists over an extended period. This preliminary action maintains therapeutic drug levels in the tumor microenvironment continuously, thereby achieving both prolonged therapeutic effects and improved tumor regression in preclinical models.
Solution Approach 2:
The patent changes the physical state and release kinetics of TRAIL receptor agonists by formulating them with thermally responsive polypeptides. This parameter change transforms the drug delivery system from short-acting to sustained-release, extending the duration of action while maintaining or enhancing tumor regression efficiency through continuous therapeutic exposure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of TRAIL receptor agonists with sensitizing agents significantly increases the potency of TRAIL in resistant cancer cells, achieving synergistic cytotoxicity and apoptosis, with the depot formulation providing prolonged therapeutic effects and improved tumor regression in preclinical models.
Implementation Method 1
a TRAIL receptor agonist fused to a thermally responsive polypeptide that has a transition temperature (Tt) between about 20° C. and 33° C., and forms a sustained release subcutaneous depot in the subject upon administration
Data Source
AI summary
Embodiments of the present disclosure relate generally to the treatment of cancer involving activation of the tumor necrosis factor-related apoptosis inducing ligand receptor (TRAILR) pathway. In particular, the present disclosure provides compositions and methods for the identification of genes conferring TRAIL resistance, and the development of rational drug combinations targeting these genes. The therapeutic drug combinations of the present disclosure function synergistically to sensitize cancer cells to TRAIL-resistant cancers.